Lisata Therapeutics (NASDAQ:LSTA) Trading Up 0.9% – Time to Buy?

Shares of Lisata Therapeutics, Inc. (NASDAQ:LSTA) were up 0.9% on Monday . The stock traded as high as $2.33 and last traded at $2.28. Approximately 26,865 shares traded hands during trading, an increase of 27% from the average daily volume of 21,225 shares. The stock had previously closed at $2.26.

Lisata Therapeutics Trading Up 0.9 %

The company’s 50-day moving average price is $2.27 and its two-hundred day moving average price is $2.71. The company has a market cap of $19.65 million, a P/E ratio of -0.91 and a beta of 1.00.

Lisata Therapeutics (NASDAQ:LSTA) last announced its quarterly earnings data on Thursday, February 27th. The company reported ($0.55) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.76) by $0.21. The firm had revenue of $1.00 million for the quarter. As a group, analysts anticipate that Lisata Therapeutics, Inc. will post -2.66 earnings per share for the current year.

Hedge Funds Weigh In On Lisata Therapeutics

An institutional investor recently bought a new position in Lisata Therapeutics stock. Citadel Advisors LLC bought a new position in shares of Lisata Therapeutics, Inc. (NASDAQ:LSTA) during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor bought 23,273 shares of the company’s stock, valued at approximately $69,000. Citadel Advisors LLC owned 0.28% of Lisata Therapeutics as of its most recent filing with the Securities and Exchange Commission (SEC). Institutional investors own 8.94% of the company’s stock.

About Lisata Therapeutics

Lisata Therapeutics, Inc, a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of innovative therapies for the treatment of solid tumors and other diseases. Its product candidates include LSTA1, which is in Phase 2a and 2b clinical studies for the treatment of solid tumor, including metastatic pancreatic ductal adenocarcinoma (mPDAC), in combination with a range of anti-cancer regimens; XOWNA that is in Phase IIa clinical trial for the treatment of coronary microvascular dysfunction; and CD34+ cell therapy for the treatment of chronic kidney disease.